Skip to Content

Stemcell Holdings Inc Ordinary Shares STMM Stock Quote

| Rating as of

Morningstar‘s Stock Analysis STMM

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics STMM

Company Profile STMM

Business Description

Stemcell Holdings Inc, through its subsidiary, is engaged in the regenerative medicine-related business which includes but is not limited to providing technical assistance to the culturing, storing and delivery of stem cells and administrative and consulting services to clinics. The company provides two different options for stem cell regenerative therapy: autologous adipose derived mesenchymal stem cells and natural killer cells.

Level 11, 3-6-7 Kitaaoyama, Minato
Tokyo, 107-0061, Japan
T +81 357785294
Industry Biotechnology
Most Recent Earnings Sep 30, 2018
Fiscal Year End Dec 31, 2022
Stock Type